These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26891869)

  • 1. The molecular mechanisms between metabolic syndrome and breast cancer.
    Chen Y; Wen YY; Li ZR; Luo DL; Zhang XH
    Biochem Biophys Res Commun; 2016 Mar; 471(4):391-5. PubMed ID: 26891869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease and metabolic syndrome in postmenopausal women.
    Rodrigues MH; Bruno AS; Nahas-Neto J; Santos ME; Nahas EA
    Gynecol Endocrinol; 2014 May; 30(5):325-9. PubMed ID: 24460502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer.
    Vona-Davis L; Howard-McNatt M; Rose DP
    Obes Rev; 2007 Sep; 8(5):395-408. PubMed ID: 17716297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty pancreas disease.
    Alempijevic T; Dragasevic S; Zec S; Popovic D; Milosavljevic T
    Postgrad Med J; 2017 Apr; 93(1098):226-230. PubMed ID: 28069746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
    Yki-Järvinen H
    Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials.
    Sáez-Lara MJ; Robles-Sanchez C; Ruiz-Ojeda FJ; Plaza-Diaz J; Gil A
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlations of insulin resistance and neoplasms].
    Suba Z; Ujpál M
    Magy Onkol; 2006; 50(2):127-35. PubMed ID: 16888676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolic syndrome and nonalcoholic fatty liver disease.
    Collantes RS; Ong JP; Younossi ZM
    Panminerva Med; 2006 Mar; 48(1):41-8. PubMed ID: 16633331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups.
    ; Lonardo A; Bellentani S; Argo CK; Ballestri S; Byrne CD; Caldwell SH; Cortez-Pinto H; Grieco A; Machado MV; Miele L; Targher G
    Dig Liver Dis; 2015 Dec; 47(12):997-1006. PubMed ID: 26454786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The metabolic syndrome and type-2 diabetes mellitus as conditions predisposing for malignant tumors].
    Halmos T; Suba I
    Orv Hetil; 2008 Dec; 149(51):2403-11. PubMed ID: 19073451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome in young people.
    Poyrazoglu S; Bas F; Darendeliler F
    Curr Opin Endocrinol Diabetes Obes; 2014 Feb; 21(1):56-63. PubMed ID: 24247648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abdominal adiposity and cardiometabolic risk: do we have all the answers?
    Haffner SM
    Am J Med; 2007 Sep; 120(9 Suppl 1):S10-6; discussion S16-7. PubMed ID: 17720354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New perspective on type 2 diabetes, dyslipidemia and non-alcoholic fatty liver disease.
    Matsuzaka T; Shimano H
    J Diabetes Investig; 2020 May; 11(3):532-534. PubMed ID: 32232972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sleep and metabolic disorders].
    Micić DD; Šumarac-Dumanović M; Šušić V; Pejković D; Polovina S
    Glas Srp Akad Nauka Med; 2011; (51):5-25. PubMed ID: 22165724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of obesity and metabolic syndrome on chronic hepatitis C.
    Goossens N; Negro F
    Clin Liver Dis; 2014 Feb; 18(1):147-56. PubMed ID: 24274870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models.
    den Boer M; Voshol PJ; Kuipers F; Havekes LM; Romijn JA
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):644-9. PubMed ID: 14715643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin resistance in obesity as the underlying cause for the metabolic syndrome.
    Gallagher EJ; Leroith D; Karnieli E
    Mt Sinai J Med; 2010; 77(5):511-23. PubMed ID: 20960553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biology of metabolic syndrome in a vascular patient.
    Vykoukal D; Davies MG
    Vascular; 2012 Jun; 20(3):156-65. PubMed ID: 22700582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.